Skip to main content

Advertisement

Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice

Fig. 1

Systemic human MSC transplantation ameliorates the bone loss in MRL/lpr mice. ac Morphological analyses of mouse tibias. a Representative micro-computed tomography (microCT) images of trabecular bone structures (yellow-dashed areas). Pre-Tx (16w) pre-transplant stage of MRL/lpr mice at 16 weeks of age; Post-Tx (20w) post-transplant stage of MRL/lpr mice at 20 weeks of age. b Bone mineral density (BMD). c Trabecular bone parameter assay. BV/TV bone volume ratio to tissue volume; Tb.N trabecular number; Tb.Sp trabecular separation; Tb.Th trabecular thickness. d, e In vivo osteoclast activity assay. d ELISA analyses of mouse serum. CTX C-terminal telopeptides of type I collagen; sRANKL soluble RANKL. e Histological analysis of recipient tibias by TRAP staining. TRAP+ cells TRAP-positive osteoclast-like cells. hBMMSC-T human bone marrow mesenchymal stem cell-transplanted MRL/lpr mice at 20 weeks; Pre-MRL/lpr pre-transplant MRL/lpr mice at 16 weeks of age; SHED-T stem cells from exfoliated deciduous teeth-transplanted MRL/lpr mice at 20 weeks. n = 5 for all groups. *P < 0.05, **P < 0.01, ***P < 0.005. Values are shown as means ± SD

Back to article page